Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 294

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 294
---
───────

  An increase in sales of Sulanda to $49.0 million for the year ended December 31, 2024 from $43.9 million for the year ended December 31, 2023, offset by:  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Table of Contents

  A decrease in sales of Orpathys (primarily to AstraZeneca) to $24.5 million for the year ended December 31, 2024 (of which $13.6 million was royalty revenue attributable from in-market sales of...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Other revenue in Oncology/Immunology decreased to $91.8 million for the year ended December 31, 2024 from $364.4 million for the year ended December 31, 2023 primarily due to:

  A decrease in Takeda collaboration revenue to $67.0 million for the year ended December 31, 2024 (which primarily includes $30.9 million was the revenue recognized from the $400 million upfront...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  $6.0 million milestone revenue recognized from AstraZeneca for the year ended December 31, 2024 following NDA acceptance in China for Orpathys combined with Tagrisso.  

Revenue from our Other Ventures decreased to $266.8 million for the year ended December 31, 2024 from $309.4 million for the year ended December 31, 2023, primarily due lower COVID-related prescription drug product sales and the disposal of Hutchison Hain Organic and HUTCHMED Science Nutrition in December 2023.

Cost of Revenue

Our cost of revenue decreased by 9.3% to $348.9 million for the year ended December 31, 2024 from $384.4 million for the year ended December 31, 2023. This decrease was primarily due to lower sales from our Other Ventures operations.

Cost of revenue from our Other Ventures decreased by 12.5% to $256.1 million for the year ended December 31, 2024 from $292.7 million for the year ended December 31, 202